Aminobenzoic acids and derivatives
Medchemexpress LLC Masitinib mesylate | 1048007-93-7 | MFCD12546334 | 100.0% | 594.75 g/mol | C29H34N6O4S2 | 5 MG
Masitinib mesylate is the mesylate salt form of masitinib, a small-molecule tyrosine kinase inhibitor. It is supplied as a high-purity analytical and research compound for in vitro and analytical applications and selectively inhibits c-Kit, PDGFR, and Src family kinases.
- Purity 99.98%.
- Molecular weight 594.75 g/mol.
- Molecular formula C29H34N6O4S2.
- Solubility in DMSO ≥ 30 mg/mL.
- Intended for research and analytical use.
- Available in a 5 mg pack size.
Selleck Chemical LLC Lenvatinib Mesylate S5240-1g
Lenvatinib Mesylate is a synthetic orally available tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3) fibroblast growth factor receptor (FGFR1-4) platelet-derived growth factor receptor (PDGFR ) stem cell factor receptor (Kit (c-Kit)) and rearranged during transfection (RET (c-RET)) Lenvatinib Mesylate has potential antineoplastic activity
Medchemexpress LLC AZ7550 mesylate (AZ7550 trimesylate salt) | 2319837-99-3 | 98.7% | 773.90 g·mol⁻¹ | C30H43N7O11S3 | 10 MG
AZ7550 mesylate is the mesylate (trimesylate) salt of AZ7550, an active metabolite of AZD9291 that inhibits IGF1R (IC50 = 1.6 μM). It is provided as an analytical standard for biochemical and cellular research and is offered in small milligram packages and solution formats for assay use.
- Mesylate (trimesylate) salt form for improved handling and solubility.
- Reported IGF1R inhibitory activity with IC50 = 1.6 μM.
- High purity (~98.7%), suitable as an analytical standard.
- Molecular weight 773.90 g·mol⁻¹ and formula C30H43N7O11S3.
- Available in small quantities (5-100 mg) and as DMSO solutions for assay readiness.
Cayman Chemical WIN 55 212 mesylate
A racemic mixture of (+)-WIN 55,212-2 and (−)-WIN 55,212-3; inhibits electrically induced contractions in mouse vas deferens preparations (IC50 = 0.006 µM) and reduces PG synthesis by 35% in mouse brain microsomes at 30 µM; decreases acetylcholine-induced writhing in mice (ED50 = 0.25 mg/kg); induces hypolocomotion, analgesia, hypothermia, and catalepsy in mice (ED50s = 1.09, 0.5, 3.01 and 6.8 mg/kg, respectively)
Medchemexpress LLC Eprosartan mesylate | 144143-96-4 | MFCD08141807 | 100.0% | 520.62 g/mol | C24H28N2O7S2 | 10 MG
Eprosartan mesylate is a selective, competitive, orally active angiotensin II receptor antagonist supplied for research use in pharmacology and biochemical studies. It is provided as a high-purity solid and as solution formulations for in vitro assays, and is supported by technical documentation (datasheet, COA, SDS) for laboratory handling and experimental planning.
- Selective angiotensin II receptor antagonist suitable for receptor binding and functional assays.
- High purity appropriate for research applications (listed at 99.95%).
- Available as a solid and as a 10 mM solution in DMSO for in vitro use.
- Supported by datasheet, certificate of analysis, and safety data sheet.
- Stable when stored sealed and protected from moisture; specific solvent storage conditions available.
Medchemexpress LLC Lenvatinib (mesylate) | 857890-39-2 | 99.7% | 522.96 | 25 MG
Lenvatinib mesylate is an oral, multi-targeted tyrosine kinase inhibitor. It inhibits vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor (PDGFR), KIT, and RET. The compound demonstrates potent antitumor activities.
- Inhibits VEGFR2 with an IC50 of 4 nM
- Inhibits VEGFR3 with an IC50 of 5.2 nM
- Inhibits VEGFR1 with an IC50 of 22 nM
- Inhibits PDGFRα with an IC50 of 51 nM
- Inhibits PDGFRβ with an IC50 of 39 nM
- Inhibits FGFR1 with an IC50 of 46 nM
- Inhibits KIT with an IC50 of 100 nM
- Significantly inhibits local tumor growth and metastasis in preclinical models
eMolecules 138-14-7 | Deferoxamine Mesylate | Target Molecule | MFCD00058605 | 656.790 | C26H52N6O11S | 0.000 | CS(O)(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN | 50mg | 335410880
Deferoxamine Mesylate | Target Molecule | 138-14-7 | MFCD00058605 | 656.790 | C26H52N6O11S | 0.000 | CS(O)(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN | 50mg | 335410880
![eMolecules 169869-90-3 | Exatecan mesylate | Ambeed | MFCD04113012 | 531.560 | C25H26FN3O7S | 98.000 | CS(O)(=O)=O.CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45 | 100mg | 784396076](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000126098.jpg-250.jpg)
eMolecules 169869-90-3 | Exatecan mesylate | Ambeed | MFCD04113012 | 531.560 | C25H26FN3O7S | 98.000 | CS(O)(=O)=O.CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45 | 100mg | 784396076
Exatecan mesylate | Ambeed | 169869-90-3 | MFCD04113012 | 531.560 | C25H26FN3O7S | 98.000 | CS(O)(=O)=O.CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45 | 100mg | 784396076
Medchemexpress LLC NSC243928 mesylate | 59988-01-1 | 99.3% | 503.59 g·mol⁻¹ | C23H25N3O6S2 | 5MG
NSC243928 mesylate is the mesylate salt of NSC243928, a small-molecule binder of human lymphocyte antigen 6 (LY6) that inhibits cell growth and exhibits anticancer activity in vitro. Reported activity includes induction of cell death and IC50 values in the low micromolar range against multiple cancer cell lines.
- Solid, light yellow to yellow physical form.
- Purity 99.33%.
- Molecular weight 503.59 g·mol⁻¹ and formula C23H25N3O6S2.
- Soluble in DMSO (10 mg/mL; may require sonication and warming).
- Recommended storage: solid at 4°C; solutions at -80°C (6 months) or -20°C (1 month).
- Provided in small research pack sizes and ready-to-use 10 mM DMSO solutions.
Medchemexpress LLC Encequidar mesylate | 849675-87-2 | 99.6% | 784.83 | 50 MG
Encequidar mesylate is a competitive and potent P-glycoprotein inhibitor. This product is for research use only.
- Target: P-glycoprotein
- Appearance: Solid, light yellow to yellow
- Solubility in DMSO: 25 mg/mL (31.85 mM), requires ultrasonic
- Improved in vivo absorption with microcapsule form
- Involved in clinical trials for metastatic breast cancer, breast neoplasms, and solid tumors
Medchemexpress LLC Casopitant mesylate | 414910-30-8 | 99.8% | C31H39F7N4O5S | 1 ML
Casopitant mesylate is a potent, selective, brain-permeable, and orally active neurokinin 1 (NK1) receptor antagonist. It functions as a second-in-class antiemetic by antagonizing the emetogenic effect of Substance P. This compound also acts as a substrate and a weak-to-moderate inhibitor of CYP3A4, making it suitable for addressing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).
- Potent, selective, brain-permeable, and orally active
- Functions as a neurokinin 1 (NK1) receptor antagonist
- Antagonizes the emetogenic effect of substance P
- Substrate and weak-to-moderate inhibitor of CYP3A4
- Used for chemotherapy-induced nausea and vomiting (CINV)
- Used for postoperative nausea and vomiting (PONV)
Medchemexpress LLC AZ7550 Mesylate | 2319837-99-3 | 98.7% | 100 MG
AZ7550 Mesylate is an active metabolite of AZD9291 that inhibits IGF1R activity with an IC50 of 1.6 μM. This product is intended for research use only.
- Inhibits IGF1R with an IC50 of 1.6 μM.
- Shows potency and selectivity profile similar to AZD9291.
- Inhibits DM cell line H1975, AM cell line PC9, and WT cell line LoVo.
- Inhibits DM antiproliferative cell line H1975, AM cell line PC9, and WT antiproliferative cell line Calu3.
Apexbio Technology LLC Gabexate mesylate 56974-61-9 10mM (in 1mL DMSO)
Gabexate mesylate (CAS 56974-61-9) is a synthetic non-antigenic inhibitor targeting serine proteases including human and bovine trypsin It competitively binds the primary specificity pocket (S1) of trypsin enzymes interacting primarily through its carbonyl group at the enzyme s oxyanion binding site Reported Ki values are 3 4 nM for human trypsin and 180 nM for bovine trypsin Gabexate mesylate also inhibits nitric oxide synthases (cNOS and iNOS Ki 150 M and 5 mM respectively) suppressing LPS/IFN -induced NO production (EC50 250 M) It is employed in research related to pancreatitis coagulation disorders and inflammation
eMolecules 138-14-7 | Deferoxamine Mesylate | Target Molecule | MFCD00058605 | 656.790 | C26H52N6O11S | 0.000 | CS(O)(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN | 500mg | 376014295
Deferoxamine Mesylate | Target Molecule | 138-14-7 | MFCD00058605 | 656.790 | C26H52N6O11S | 0.000 | CS(O)(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN | 500mg | 376014295
Medchemexpress LLC FFN 102 mesylate | 1883548-92-2 | 99.0% | 335.76 | 50 MG
FFN 102 mesylate is a synthetic biogenic neurotransmitter analogue, characterized by its pH-dependent fluorescence and electrical activity. It is intended for research use only. For proper storage, it should be kept at -20°C in sealed storage, away from moisture. When dissolved, stock solutions in DMSO or water have specific storage conditions: -80°C for 6 months or -20°C for 1 month (sealed, away from moisture).
- Requires ultrasonic treatment for dissolution in DMSO and water.
- Hygroscopic nature of DMSO impacts product solubility.
- Dilute aqueous stock solutions to working solutions, then filter and sterilize with a 0.22 μm filter before use.